セラノスティクス横浜がお届けする最新のセラノスティクス　セラヨコ・ライブラリー

Information
2025.03.24　
サイトを公開しました。

文献のご紹介　※セラヨコ・トーク付き

The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy

Eur Urol Oncol. 2024 Nov 28:S2588-9311(24)00249-9.
DOI　10.1016/
j.euo.2024.11.002. Online ahead of print.

Prostate-specific Membrane Antigen Reporting and Data System Version 2.0

DOI　0.1016/
j.eururo.2023.06.008

Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET

Journal of Nuclear Medicine February 2025, jnumed.124.268340;
DOI　10.2967/
jnumed.124.268340

61Cu-PSMA–Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging

DOI　10.2967/
junmed.123.267126

Low-and High- Volume Disease in Mertastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study

Journal of Nuclear Medicine January 2025, 66 (1) 54-60;
DOI 10.2967/
jnumed.124.268441

177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2)Predicts Short Progression-Free Survival for PatientsUndergoing177 Lu-PSMA-I&T Therapy

J Nucl Med 2023; 64:410-415
DOI　10.2967/
jnumed.122.264677

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

DOI　10.1016/
S1470-2045(25)00009-9

Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery

DOI　10.2967/
jnumed.124.268151

1 2 次へ »

※セラヨコ・トーク＝抄読会でのセラヨコメンバーのつぶやき

動画コンテンツ